The Brain Disorders drugs market was valued at USD 79.40 billion in 2021 and is expected to reach USD 125.60 billion by 2029, growing at a CAGR of 5.9% from 2022 to 2029. The prevalence of Brain Disorders is rising globally due to an ageing population and an average lifespan. The need for diagnostic tools has increased recently due to an increase in the prevalence of neurological disorders. Increased awareness, an increase in the prevalence of neurological disorders, and a robust product pipeline for the treatment of Neurorehabilitation are the main drivers of market growth. 533,172 people died from neurological conditions in 2019, of whom 320,043 (60%) were women and 213,129 (40%) were men. The market for Brain Disorders is expected to expand as a result of the burden of neurological disorders, which will increase demand for treatments and efficient treatment options.

The market treating brain tumors worldwide had a market value of US$ 2,946.17 million in 2022, and it is anticipated to reach US$ 5,904.82 million by 2032, growing at a CAGR of 7.2%. Key factors that are anticipated to foster the growth of the brain tumor diagnosis market globally include the rising prevalence of such cancer and the expanding geriatric population. The global demand for brain surgery treatment is anticipated to grow at a CAGR of 7.2%between 2022 and 2032, reaching a total of US$ 5,904.82 Million in 2032. (FMI).Sales increased significantly between 2017 and 2021, with a 6.8% CAGR.

The global market for stroke diagnostic and therapeutic products was estimated to be worth USD 32.69 billion in 2021 and is expected to reach USD 65.45 billion by 2030, growing at a projected CAGR of 8% from 2022 to2030. Expanding geriatric populations and rising Neuroscience disease rates will be the main factors driving the stroke management market. Over 70 years old made up 56% of aortic valve stenosis patients in Europe. Additionally, a number of government agencies have started awareness campaigns to lower the frequency of strokes and brain disorders among the elderly population. For instance, the Patient Protection and Affordable Care Act (ACA) in the United States provides health coverage to more than 20 million people, including senior citizens.

The size of the global Parkinson's disease treatment market was estimated at USD 4.28 billion in2021, and it is anticipated to increase at a CAGR of 12.1% from 2022 to 2030.The growth for treatments for Parkinson's disease was valued at USD 4.28 billion in 2021, and from 2022to 2030, it is projected to grow at a CAGR of 12.1%. In addition, a significant market trend for Parkinson's disease that is supporting the industry's expansion is a strong pipeline of new drug development. In the US, there are almost 1 million people with Parkinson's disease.

The size of the global market for Alzheimer's therapeutics was estimated at USD 4.04 billion in 2021, and it is anticipated to grow at a CAGR of 16.2% from 2022 to 2030. Market expansion is anticipated to be fueled by the increasing prevalence of Alzheimer's disease and the approval of disease-modifying treatments. Alzheimer's disease was present in about 6.2 million Americans 65 and older in 2021; by 2060, that number is expected to rise to about 13.8 million. Due to their longer life expectancy, women are more likely than men to be diagnosed with Alzheimer's disease. Additionally, Alzheimer's disease is quickly over taking other neurodegenerative diseases as the leading cause of death and a major contributor to physical impairment that calls for urgent medical attention.

The market for treatments for dementia was valued at USD 13,459.39 million in 2021, growing at a CAGR of 8.28% during the anticipated period 2022 - 2027. The market for dementia medications is anticipated to be significantly impacted by theCOVID-19 pandemic outbreak. The market for dementia drugs is likely to grow as a result of the ageing population suffering from a variety of disorders and the rising prevalence of target disorders. The increasing incidence of dementia cases is one of the main factors influencing the global market for drugs to treat it. Alzheimer's Disease International estimates that there will be more than50 million dementia sufferers worldwide in 2020. This number is anticipated to double every 20 years, rising to 82 million in 2030 and 152 million in 2050.   

The market for traumatic brain injury assessment and management tools were estimated to be worth USD 2.89 billion in 2021, and it is anticipated to expand at a CAGR of 7.5% from 2022 to 2030. The main factors anticipated to propel the growth of the traumatic brain injuries (TBIs) assessment and management devices market is the rising prevalence of TBIs, rising patient preference for minimally invasive procedures, as well as increased awareness regarding brain injury treatment.

The growth for Brain disorders diagnostics is anticipated to reach US$12,162.6 million in 2019 and grow at a7.6% CAGR during the forecast period (2019–2027). Tools for diagnosing neurological disorders include medical equipment for conditions like Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis. Imaging tools like computed tomography (CT), magnetic reason acne imaging (MRI), and in vitro diagnostic tools like biomarkers and biopsy are among the devices that are primarily used in diagnosis. The need for diagnostic tools has increased recently due to an increase in the prevalence of neurological disorders. For instance, the Alzheimer's Association reported in 2018 that 5.7 million Americans across all age groups experienced dementia and Alzheimer's in 2017.

The size oft he global market for mental health and Neurorehabilitation was US$ 381.98 billion in 2020; it is projected to grow to US$ 527.44 billion by 2030, at a CAGR of 3.40 percent. The global mental health market is divided into sections based on region, age group, disorder, and service. With a projected CAGR of 3.5% from 2021 to 2030, the global market for mental health is expected to grow from its estimated value of $383.31 million in 2020 to$537.97 million by 2030.

Neuropsychology is the discipline which investigates the relations between brain disorders conferences processes and mechanisms on one hand, and cognition and behavioral control on the other. Neuropsychology is a branch of psychology. It's concerned with how a person's cognition and behavior are related to the brain and the rest of the nervous system. Professionals in this branch of psychology frequently concentration how injuries or illnesses of the brain affect cognitive and behavioral functions.

Multiple sclerosis is a chronic complaint that affects the central nervous system, which is the brain, spinal cord, and optical nerves. This can lead to a wide range of symptoms throughout the body. Scientists don't know exactly what causes Multiple Sclerosis, but they believe Trusted Source it's an autoimmune complaint that affects the Central Nervous System (CNS). When a person has an autoimmune complaint, the immune system attacks healthy tissue, just as it might attack a contagion or bacteria.